Health Care & Life Sciences » Pharmaceuticals | Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc. | Ownership

Companies that own Pieris Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BVF Partners LP
5,626,295
10.41%
279,457
2.1%
07/12/2018
OrbiMed Advisors LLC
3,140,000
5.81%
-2,410,000
0.18%
06/30/2018
BlackRock Fund Advisors
2,383,266
4.41%
743,866
0%
06/30/2018
Acadian Asset Management LLC
2,124,873
3.93%
664,032
0.03%
06/30/2018
Tekla Capital Management LLC
2,087,380
3.86%
0
0.38%
06/30/2018
Aquilo Capital Management LLC
1,975,098
3.66%
1,975,098
9.11%
06/30/2018
Renaissance Technologies LLC
1,522,600
2.82%
-7,200
0.01%
06/30/2018
Prosight Management LP
1,360,000
2.52%
796,237
5.16%
06/30/2018
Millennium Management LLC
1,081,470
2%
-742,639
0.01%
06/30/2018
Arrowstreet Capital LP
1,017,890
1.88%
-11,908
0.01%
06/30/2018

About Pieris Pharmaceuticals

View Profile
Address
255 State Street
Boston Massachusetts 02109
United States
Employees -
Website http://www.pieris.com
Updated 07/08/2019
Pieris Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with an unmet medical need. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.